Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2026-05-07 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
上海德禾翰通律师事务所关于安徽峆一药业股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2025 Annual General Meeting (AGM) of Anhui Lingyi Pharmaceutical Co., Ltd. It details the legality of the AGM's convening, attendance, voting procedures, and results. The document includes verification of shareholder qualifications, voting outcomes on various resolutions including the annual report, financial statements, and other corporate matters. It does not contain the actual annual report or financial statements but rather confirms the validity of the AGM process and resolutions passed. This type of document is a legal opinion related to the AGM, not the AGM materials themselves or the annual report. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official voting results and legitimacy of the shareholder meeting proceedings.
2026-05-07 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2025 Annual General Meeting (AGM) resolution announcement for 安徽岭一药业股份有限公司. It details the meeting date, attendance, agenda items, and voting results on various proposals including the 2025 annual report, financial statements, budget, dividend distribution plan, auditor appointment, and other corporate matters. The document is a formal announcement of the resolutions passed at the AGM, including voting outcomes and legal opinions confirming the meeting's compliance with laws and company bylaws. It does not contain the full annual report or financial statements themselves but reports on the shareholder meeting decisions. The document length is 3285 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-07 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 安徽岭一药业股份有限公司, dated May 2026. It contains detailed provisions on company organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. It references relevant laws and regulatory frameworks such as the Company Law of China, Securities Law, and Beijing Stock Exchange listing rules. The content is a comprehensive governance document that sets out the internal rules and structure of the company rather than financial results, audit opinions, or announcements. It is not a report of financial performance, nor an announcement of voting results or management changes. It is a governance document detailing the company's internal rules and board structure. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance document, not a brief announcement or summary.
2026-05-07 Chinese
2025年度独立董事述职报告（杨模荣）
Audit Report / Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Xuyi Pharmaceutical Co., Ltd. for the year 2025. It includes the director's attendance at board and shareholder meetings, participation in committees, exercise of independent director powers, communication with auditors, protection of minority shareholders, and evaluation of company governance and financial reporting. The document is a comprehensive annual report on the independent director's duties and activities, which is typical of an Audit Report / Information (AR) or a governance-related report. However, it is not a full Annual Report (10-K) or a Management Report (MDA) because it focuses specifically on the independent director's role and oversight rather than full financial performance or management discussion. It is also not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content rather than just an announcement. The document aligns best with the Audit Report / Information (AR) category as it discusses audit committee activities, internal control evaluations, and oversight of financial reporting and audit processes by the independent director. FY 2025
2026-04-15 Chinese
2025年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary". It contains detailed financial data for the year 2025, including assets, liabilities, net profit, earnings per share, and shareholder information. It also includes management assurances about the accuracy of the report and an audit opinion from an accounting firm. The length of the document (7323 characters) and the detailed financial and operational information indicate this is the actual annual report or a substantial part of it, not just an announcement or summary notice. Therefore, it fits the definition of an Annual Report (10-K). FY 2025
2026-04-15 Chinese
2025年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2025' which translates to 'Annual Report 2025'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal controls, and financial accounting reports. It includes audited financial data, management's discussion of business and financial performance, risk factors, and detailed financial statements. The document length is substantial (15,000 characters) and contains comprehensive financial and operational information for the fiscal year 2025. There is also mention of an unqualified audit opinion from the accounting firm. These characteristics clearly identify the document as a full Annual Report (10-K equivalent). FY 2025
2026-04-15 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.